Seagen Inc. (SGEN)

Last Closing Price: 180.11 (2022-07-01)

Company Description

Seagen, Inc., a biotechnology company, focuses on developing & commercializing therapies targeted for the treatment of cancer. Adcetris, a lead FDA approved marketed product at Seagen, is used for treating Hodgkin lymphoma, certain T-cell lymphomas, other cancers in the U.S., Europe & several countries. Seagen has an agreement with Takeda Pharmaceutical Company Ltd. for the further development and commercialization of Adcetris. Seagen retains all rights to sell Adcetris in the U.S. and Canada, while Takeda has commercial rights to the drug in the rest of the world. The FDA granted approvals to Seagen's several drugs named Padcev, for treating advanced/metastatic urothelial cancer; Tukysa and Tivdak for treating adult patients with locally advanced/metastatic HER2-positive breast cancer and for the treatment of recurrent/metastatic cervical cancer in adult patients respectively. The company also has license agreements with partners like Merck, Roche, GlaxoSmithKline, Astellas, AbbVie, Bristol-Myers and Genmab.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $1.57B
Net Income (Most Recent Fiscal Year) $-674.47M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) 19.87
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 11.06
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) -41.32%
Net Margin (Trailing 12 Months) -41.32%
Return on Equity (Trailing 12 Months) -21.86%
Return on Assets (Trailing 12 Months) -18.07%
Current Ratio (Most Recent Fiscal Quarter) 5.22
Quick Ratio (Most Recent Fiscal Quarter) 4.70
Debt to Common Equity (Most Recent Fiscal Quarter) 0.00
Inventory Turnover (Trailing 12 Months) 1.63
Book Value per Share (Most Recent Fiscal Quarter) $16.76
Earnings per Share (Most Recent Fiscal Quarter) $-0.74
Earnings per Share (Most Recent Fiscal Year) $-3.70
Diluted Earnings per Share (Trailing 12 Months) $-3.77
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 184.08M
Free Float 133.82M
Market Capitalization $33.15B
Average Volume (Last 20 Days) 1.75M
Beta (Past 60 Months) 0.60
Percentage Held By Insiders (Latest Annual Proxy Report) 27.30%
Percentage Held By Institutions (Latest 13F Reports) 90.37%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%